NKTR-214: Clinical Trials

7 completed, 6 terminated, 1 active not recruiting, 1 withdrawn. 9 Phase 1, 9 Phase 2, 3 Phase 3.

By phase and status

Phase	Trials	Status
Phase 1	9	Completed 4, Terminated 4, Withdrawn 1
Phase 2	9	Terminated 5, Completed 3, Active not recruiting 1
Phase 3	3	Completed 2, Terminated 1

Follow NKTR-214: new trials by email Literature Review of NKTR-214 trials Research Report on NKTR-214

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Bempegaldesleukin (NKTR-214) With Radiation and Anti-PD-1 Immunotherapy for Head and Neck Squamous Cell Carcinoma NKTR-214, anti-PD-1 therapy, Palliative Radiation - Head and Neck Cancer	Phase 2	Terminated	University of Wisconsin, Madison	5	2021-08-05	2024-04-04
A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer Nivolumab, NKTR-214 - Ependymoma, Ewing Sarcoma	Phase 1 / Phase 2	Terminated	Bristol-Myers Squibb	15	2021-06-03	2023-03-24
A Placebo Controlled Trial of Bempegaldesleukin (BEMPEG; NKTR-214) With Standard of Care in Patients With Mild COVID-19 Bempegaldesleukin, Standard of Care, Placebo - Covid-19, Coronavirus Disease 2019	Phase 1	Completed	Nektar Therapeutics	30	2020-11-13	2024-03-12
Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence Bempegaldesleukin, Nivolumab - Melanoma, Melanoma Stage III	Phase 3	Terminated	Nektar Therapeutics	765	2020-07-27	2023-04-21
A Study of Nivolumab Plus Bempegaldesleukin (Bempeg/NKTR-214) vs Nivolumab Alone vs Standard of Care in Participants With Bladder Cancer That May Have Invaded The Muscle Wall of the Bladder and Who Cannot Get Cisplatin, A Type of Medicine Given To Treat Bladder Cancer Nivolumab, Radical cystectomy (RC), Bempegaldesleukin - Bladder Cancer, Bladder Tumor	Phase 3	Completed	Bristol-Myers Squibb	114	2020-02-05	2024-06-27
Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors avelumab, Bempegaldesleukin, talazoparib - Squamous Cell Carcinoma of the Head and Neck (SCCHN), Metastatic Castration Resistant Prostate Cancer (mCRPC)	Phase 1 / Phase 2	Terminated	Pfizer	3	2019-12-30	2021-10-14
A Single-Arm Study of Bempegaldesleukin (NKTR-214) Plus Nivolumab in Cisplatin Ineligible Patients Who Have Locally Advanced or Metastatic Urothelial Cancer Bempegaldesleukin, Nivolumab - Urinary Bladder Neoplasm, Neoplasm Metastasis	Phase 2	Completed	Nektar Therapeutics	192	2019-04-29	2023-03-28
An Investigational Study of NKTR-214 Combined With Nivolumab in Japanese Participants With Advanced Solid Tumors NKTR-214, Nivolumab - Advanced Cancer	Phase 1	Completed	Bristol-Myers Squibb	3	2019-04-09	2021-10-04
A Study of TAK-659 in Combination With NKTR-214 in Participants With Advanced Non-Hodgkin Lymphoma (NHL) TAK-659, NKTR-214 - Lymphoma, Non-Hodgkin	Phase 1	Withdrawn	Calithera Biosciences, Inc		2019-04-03	2023-02-08
A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma NKTR-214, Nivolumab - Melanoma	Phase 3	Completed	Bristol-Myers Squibb	783	2018-09-21	2025-04-01
A Study to Evaluate Safety and Efficacy of Multiple Dosing With VB10.NEO and Bempegaldesleukin (NKTR-214) Immunotherapy in Patients With Locally Advanced or Metastatic Cancer VB10.NEO, Bempegaldesleukin - Locally Advanced or Metastatic Solid Tumours	Phase 1 / Phase 2	Completed	Nykode Therapeutics ASA	41	2018-04-04	2023-04-21
REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies NKTR-262, bempegaldesleukin, nivolumab - Melanoma, Merkel Cell Carcinoma	Phase 1 / Phase 2	Terminated	Nektar Therapeutics	64	2018-03-15	2023-03-08
A Study of NKTR-214 in Combination With Nivolumab in Patients With Metastatic and/or Locally Advanced Sarcoma NKTR-214, Nivolumab - SARCOMA	Phase 2	Active not recruiting	Memorial Sloan Kettering Cancer Center	88	2017-09-12	2026-07-22
Bempegaldesleukin and Pembrolizumab With or Without Chemotherapy in Locally Advanced or Metastatic Solid Tumors NKTR-214, Pembrolizumab, Cisplatin - Non-Small Cell Lung Cancer	Phase 1 / Phase 2	Terminated	Nektar Therapeutics	162	2017-06-09	2023-03-10
A Phase 1/2 Multicenter Dose Escalation and Expansion Study Of NKTR-214 In Subjects With Locally Advanced Or Metastatic Solid Tumors NKTR-214 - Unspecified Adult Solid Tumor, Protocol Specific	Phase 1 / Phase 2	Completed	Nektar Therapeutics	28	2015-12-01	2021-07-29

Conditions studied

Melanoma (5)  ·  Carcinoma, Renal Cell (2)  ·  Lymphoma, Non-Hodgkin (2)  ·  Neoplasm Metastasis (2)  ·  Recurrence (2)  ·  Sarcoma (2)  ·  Squamous Cell Carcinoma of Head and Neck (2)  ·  Urinary Bladder Neoplasms (2)  ·  COVID-19 (1)  ·  Carcinoma, Merkel Cell (1)  ·  Carcinoma, Non-Small-Cell Lung (1)  ·  Carcinoma, Transitional Cell (1)  ·  Colorectal Neoplasms (1)  ·  Ependymoma (1)  ·  Glioma (1)

Sponsors

Nektar Therapeutics (6)  ·  Bristol-Myers Squibb (4)  ·  Calithera Biosciences, Inc (1)  ·  Memorial Sloan Kettering Cancer Center (1)  ·  Nykode Therapeutics ASA (1)  ·  Pfizer (1)  ·  University of Wisconsin, Madison (1)

Countries

United States (13)  ·  Germany (7)  ·  Spain (7)  ·  Australia (6)  ·  France (6)  ·  Italy (5)  ·  Belgium (4)  ·  Canada (4)  ·  Greece (4)  ·  Israel (4)  ·  Netherlands (4)  ·  Poland (4)  ·  Russia (4)  ·  United Kingdom (4)  ·  Argentina (3)

Top investigators

Adam Burr, MD, PhD (1)  ·  Justine Bruce, MD (1)  ·  Paul Harari, MD (1)  ·  Sandra D'Angelo, MD (1)  ·  Zachary Morris, MD, PhD (1)

Results publications

PMID 30988166, PMID 32723187, PMID 34311780, PMID 35073733, PMID 35444059, PMID 35710741, PMID 37651676, PMID 41811823

NIH funding

2018 (4), 2016 (1), 2019 (1)